| Funding Opportunity ID: |
295725 |
| Opportunity Number: |
PAR-17-331 |
| Opportunity Title: |
Discovery of Small Molecule Immunomodulators for Cancer Therapy (R01) |
| Opportunity Category: |
Discretionary |
| Opportunity Category Explanation: |
|
| Funding Instrument Type: |
Grant |
| Category of Funding Activity: |
Education
Health |
| Category Explanation: |
|
| CFDA Number(s): |
93.395 |
| Eligible Applicants: |
State governments
County governments
City or township governments
Special district governments
Independent school districts
Public and State controlled institutions of higher education
Native American tribal governments (Federally recognized)
Public housing authorities/Indian housing authorities
Native American tribal organizations (other than Federally recognized tribal governments)
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Private institutions of higher education
For profit organizations other than small businesses
Small businesses
Others (see text field entitled “Additional Information on Eligibility” for clarification) |
| Additional Information on Eligibility: |
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
| Agency Code: |
HHS-NIH11 |
| Agency Name: |
Department of Health and Human Services
National Institutes of Health |
| Posted Date: |
Jul 20, 2017 |
| Close Date: |
May 07, 2020 |
| Last Updated Date: |
Jul 20, 2017 |
| Award Ceiling: |
|
| Award Floor: |
|
| Estimated Total Program Funding: |
|
| Expected Number of Awards: |
|
| Description: |
The purpose of this funding opportunity announcement (FOA) is to promote the discovery of novel small molecules that may enhance the ability of the immune system to selectively recognize and attack cancer cells. These small molecules could be further developed into stand-alone immunotherapeutics or synergistic partners for existing therapies, or as chemical probes for the discovery and validation of novel targets involved in anti-tumor immunity. Investigators from multiple scientific disciplines (immuno-oncology, tumor biology, screening technology, medicinal chemistry, and pharmacology) are encouraged to establish collaborative teams to discover and develop novel small molecule immunomodulators for cancer therapy. This FOA encourages the design of research projects that utilize the following phases of discovery research: 1) assay development specifically designed for immuno-oncology targets with the intent to screen for novel small molecule compounds that show potential as either probes or drugs, or as pre-therapeutic leads; 2) screen implementation for immunomodulatory targets to identify initial screening hits (from high throughput target-focused approaches or moderate throughput phenotypic- and fragment-based approaches); 3) hit validation through secondary orthogonal and counter screening assays, and hit prioritization; and 4) hit-to-lead optimization. |
| Version: |
Synopsis 1 |
